NasdaqGS - Nasdaq Real Time Price USD

Nautilus Biotechnology, Inc. (NAUT)

Compare

1.7100

-0.0600

(-3.39%)

At close: January 31 at 4:00:00 PM EST

1.7100

0.00

(0.00%)

After hours: January 31 at 4:02:45 PM EST

US Penny Stocks To Watch In January 2025

As the U.S. stock market navigates mixed performances and anticipates key economic data, investors are keeping a close eye on various sectors for potential opportunities. Penny stocks, though often seen as relics of past market eras, continue to offer intriguing possibilities by highlighting smaller or newer companies that may provide both affordability and growth potential. By focusing on those with strong financial health, investors can uncover opportunities that align with their investment...

Simply Wall St. 22 days ago

MQ

NAUT
-3.39%
TTI
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

As the U.S. stock market experiences a pullback from its recent highs, investors are keeping a close eye on economic indicators and Federal Reserve actions that could influence future trends. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover opportunities in this unique segment of the market.

Simply Wall St. last month

BDTX

NAUT
-3.39%
III
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future

Key Insights Insiders appear to have a vested interest in Nautilus Biotechnology's growth, as seen by their sizeable...

Simply Wall St. last month

NAUT
-3.39%
3 US Penny Stocks With Market Caps Up To $400M

As the U.S. stock market reaches record highs following Donald Trump's election victory, investors are keenly observing how different sectors and asset classes will perform under the new administration. Amidst this backdrop, penny stocks—often representing smaller or newer companies—remain a point of interest for those seeking unique investment opportunities. Though the term 'penny stock' might sound like a relic of past trading days, these stocks can still offer significant growth potential...

Simply Wall St. 2 months ago

NAUT
-3.39%
FRGE

PAYS
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award

Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was bestowed the 2024 Distingui

GlobeNewswire 2 months ago

NAUT
-3.39%
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” secti

GlobeNewswire 3 months ago

NAUT
-3.39%
Nautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Nautilus Biotechnology Inc (NAUT) showcases robust financial management and platform development progress, while addressing key challenges in proteomics innovation.

GuruFocus.com 3 months ago

NAUT
-3.39%
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. “I’m excited about the expanding opportunity I see for proteomics and am pleased with the progress we’re making as a business,” said Sujal Patel, CEO of Nautilus. “We consistently receive positive feedback from researchers around the world as they t

GlobeNewswire 3 months ago

NAUT
-3.39%
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 3 months ago

NAUT
-3.39%
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of t

GlobeNewswire 3 months ago

NAUT
-3.39%
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

Industry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Naut

GlobeNewswire 4 months ago

NAUT
-3.39%
Nautilus Biotechnology Insider Ups Holding During Year

From what we can see, insiders were net buyers in Nautilus Biotechnology, Inc.'s ( NASDAQ:NAUT ) during the past 12...

Simply Wall St. 5 months ago

NAUT
-3.39%
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on t

GlobeNewswire 5 months ago

NAUT
-3.39%
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw continued progress against core development goals for each of the components of our platform,” said Sujal Patel, CEO of Nautilus. “We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitati

GlobeNewswire 5 months ago

NAUT
-3.39%
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the

GlobeNewswire 6 months ago

NAUT
-3.39%
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, June 10, 2024, at 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section

GlobeNewswire 8 months ago

NAUT
-3.39%
We're Hopeful That Nautilus Biotechnology (NASDAQ:NAUT) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 8 months ago

NAUT
-3.39%
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...

Explore key financial outcomes and strategic insights from Nautilus Biotechnology's first quarter of 2024, emphasizing growth in expenses and future expectations.

GuruFocus.com 8 months ago

NAUT
-3.39%
Nautilus Biotechnology Reports First Quarter 2024 Financial Results

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus. “We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software

GlobeNewswire 8 months ago

NAUT
-3.39%
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than Expected

Details on Financial Performance and Strategic Progress Amidst Development Phase

GuruFocus.com 8 months ago

NAUT
-3.39%

Performance Overview

Return	NAUT	S&P 500
YTD	+2.40%	+2.26%
1-Year	-41.24%	+22.65%
3-Year	-55.81%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nautilus Biotechnology, Inc. (NAUT)

US Penny Stocks To Watch In January 2025

US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future

3 US Penny Stocks With Market Caps Up To $400M

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award

Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

Nautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

Nautilus Biotechnology Insider Ups Holding During Year

Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024

Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

We're Hopeful That Nautilus Biotechnology (NASDAQ:NAUT) Will Use Its Cash Wisely

Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than Expected

Performance Overview